PMID- 20332669
OWN - NLM
STAT- MEDLINE
DCOM- 20100610
LR  - 20100324
IS  - 1423-0291 (Electronic)
IS  - 1015-2008 (Linking)
VI  - 77
IP  - 2
DP  - 2010
TI  - Expression and alteration of p16 in diffuse large B cell lymphoma.
PG  - 96-105
LID - 10.1159/000278291 [doi]
AB  - OBJECTIVES: This study aimed to examine (1) the expression of P16 protein 
      relative to sites of presentation, immunophenotypic subgroups and proliferative 
      indices of tumour cells, and (2) the relationship between p16 gene alterations 
      and P16 protein overexpression in 70 cases of diffuse large B cell lymphoma 
      (DLBCL). METHODS: Expression of P16, CD10, BCL-6, MUM-1 and proliferation marker 
      (Ki-67) was demonstrated by immunohistochemistry. Fluorescence in situ 
      hybridization (FISH) was employed to detect p16 alterations. RESULTS: P16 
      overexpression was shown in 45.7% (32/70) of the DLBCL cases, and was 
      significantly correlated with CD10 (p = 0.022) and germinal centre B-cell-like 
      (GCB) phenotype (p = 0.022). High expression of P16 was inversely associated with 
      high proliferative activity (Ki-67 index greater than 75%) (p = 0.020). Of the 47 
      cases that yielded interpretable FISH results, 57.4% (27/47) showed deletions of 
      p16 and 27.7% (13/47) showed gains of p16. P16 overexpression and p16 deletions 
      were mutually exclusive (p = 0.019). There was no correlation between P16 
      overexpression and p16 gains (p = 0.621). CONCLUSIONS: The GCB and non-GCB 
      subgroups of DLBCLs show different patterns of P16 expression. High levels of P16 
      may mitigate tumour cell proliferation. Gains of p16 do not necessarily increase 
      P16 protein expression.
FAU - Lee, Ee-Soo
AU  - Lee ES
AD  - Department of Pathology, Faculty of Medicine, University of Malaya, Kuala Lumpur, 
      Malaysia.
FAU - Kim, Lian-Hua
AU  - Kim LH
FAU - Abdullah, Wan Ariffin
AU  - Abdullah WA
FAU - Peh, Suat-Cheng
AU  - Peh SC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100322
PL  - Switzerland
TA  - Pathobiology
JT  - Pathobiology : journal of immunopathology, molecular and cellular biology
JID - 9007504
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Cell Proliferation
MH  - Child
MH  - Child, Preschool
MH  - Cyclin-Dependent Kinase Inhibitor p16/genetics/*metabolism
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - *Genes, p16
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphoma, Large B-Cell, Diffuse/genetics/*metabolism/pathology
MH  - Male
MH  - Middle Aged
EDAT- 2010/03/25 06:00
MHDA- 2010/06/11 06:00
CRDT- 2010/03/25 06:00
PHST- 2009/08/17 00:00 [received]
PHST- 2009/11/16 00:00 [accepted]
PHST- 2010/03/25 06:00 [entrez]
PHST- 2010/03/25 06:00 [pubmed]
PHST- 2010/06/11 06:00 [medline]
AID - 000278291 [pii]
AID - 10.1159/000278291 [doi]
PST - ppublish
SO  - Pathobiology. 2010;77(2):96-105. doi: 10.1159/000278291. Epub 2010 Mar 22.